{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:25:34Z","timestamp":1787091934072,"version":"build-2736575974"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ultrasound in Obstet &amp;amp; Gyne"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To compare the effectiveness and safety of progestogen\u2010primed ovarian stimulation (PPOS)\n                      <jats:italic>vs<\/jats:italic>\n                      gonadotropin\u2010releasing hormone (GnRH) antagonists and\/or agonists for women undergoing assisted reproduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Scopus, Web of Science and major clinical trial registries were searched from inception until 11 November 2025 for randomized controlled trials (RCTs) comparing PPOS (e.g. medroxyprogesterone acetate, dydrogesterone, micronized progesterone) with GnRH antagonists and\/or GnRH agonists in women undergoing ovarian stimulation for\n                      <jats:italic>in\u2010vitro<\/jats:italic>\n                      fertilization or intracytoplasmic sperm injection using their own oocytes, for oocyte donation or for fertility preservation. The primary outcome was the live\u2010birth rate per woman randomized. Secondary outcomes included rates of clinical pregnancy, premature luteinizing hormone (LH) surge, moderate\/severe ovarian hyperstimulation syndrome (OHSS) and oocyte pick\u2010up (OPU) cancelation, and the number of oocytes retrieved. Risk of bias was assessed using the Cochrane revised Risk of Bias (RoB\u20092) tool and trustworthiness was evaluated using the INveStigating ProblEmatic Clinical Trials in Systematic Reviews (INSPECT\u2010SR) tool. We performed random\u2010effects meta\u2010analyses to calculate relative risk (RR) and mean difference (MD) with 95%\u2009CI, as appropriate. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty RCTs involving 4430 participants were included. No study was at low overall risk of bias; 13 had some concerns and seven were at high risk. INSPECT\u2010SR identified serious trustworthiness concerns in five studies. PPOS was compared with GnRH antagonists in 17 studies, GnRH agonists in two studies and a combined GnRH agonist\u2009+\u2009antagonist regimen in one study. Compared with GnRH antagonists, PPOS was associated with a significantly higher live\u2010birth rate (RR, 1.13 (95%\u2009CI, 1.02\u20131.25);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02; moderate certainty). This finding remained robust on sensitivity analysis excluding the study with a high risk of bias (RR, 1.11 (95%\u2009CI, 1.00\u20131.23);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.05). PPOS was also associated with a higher number of oocytes retrieved compared with GnRH antagonists (MD, 0.88 (95%\u2009CI, 0.27\u20131.50);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005; low certainty). There were no significant differences in the rates of OPU cancelation (RR, 0.82 (95%\u2009CI, 0.42\u20131.57);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.55; low certainty) or premature LH surge (RR, 0.49 (95%\u2009CI, 0.05\u20134.94);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.54) between groups. No moderate\/severe OHSS events were reported in either group across 10 studies. For the comparison of PPOS\n                      <jats:italic>vs<\/jats:italic>\n                      GnRH agonists, there were no significant differences in live\u2010birth rate (RR, 0.97 (95%\u2009CI, 0.74\u20131.26);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.80; low certainty), moderate\/severe OHSS (RR, 0.14 (95%\u2009CI, 0.01\u20132.74);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.20; very low certainty) or number of oocytes retrieved (MD, 0.91 (95%\u2009CI, \u20130.55 to 2.37);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.22; low certainty), with zero events reported for premature LH surge and OPU cancelation in both groups. In the comparison of PPOS\n                      <jats:italic>vs<\/jats:italic>\n                      combined GnRH agonist\u2009+\u2009antagonist regimen, there were no significant differences in live\u2010birth rate (RR, 1.01 (95%\u2009CI, 0.80\u20131.27);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.93; very low certainty) or OPU cancelation (RR, 0.79 (95%\u2009CI, 0.38\u20131.67);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.54; very low certainty), with no premature LH surges reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence of moderate\u2010to\u2010low certainty suggests that PPOS results in a higher number of oocytes and a higher live\u2010birth rate in the first embryo\u2010transfer cycle compared with a GnRH antagonist protocol. PPOS appears safe, with no case of severe OHSS observed across the analyzed cohorts. Given its oral administration, lower drug cost and demonstrated efficacy, PPOS represents a viable and potentially superior alternative to GnRH analogs for women undergoing ovarian stimulation for whom fresh\u2010embryo transfer is not intended. \u00a9 2026 International Society of Ultrasound in Obstetrics and Gynecology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/uog.70267","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:07:11Z","timestamp":1783642031000},"page":"188-201","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progestogen\u2010primed ovarian stimulation\n                    <i>vs<\/i>\n                    <scp>GnRH<\/scp>\n                    antagonists and\/or agonists for women undergoing assisted reproduction: systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-5607","authenticated-orcid":false,"given":"W. P.","family":"Martins","sequence":"first","affiliation":[{"name":"SEMEAR Fertilidade, Reproductive Medicine, Ribeir\u00e3o Preto  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-1616","authenticated-orcid":false,"given":"C. O.","family":"Nastri","sequence":"additional","affiliation":[{"name":"SEMEAR Fertilidade, Reproductive Medicine, Ribeir\u00e3o Preto  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2023.103639"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmaa040"},{"issue":"62","key":"e_1_2_6_4_1","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang Y","year":"2015","journal-title":"Fertil Steril"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000941"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2024.09.011"},{"key":"e_1_2_6_7_1","article-title":"Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle","volume":"11","author":"Glujovsky D","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1595232"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-025-03612-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-606X.22.05176-4"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-020-01755-0"},{"key":"e_1_2_6_12_1","article-title":"Comparing dydrogesterone versus medroxyprogesterone in progestin\u2010primed ovarian stimulation (PPOS) for patients undergoing in vitro fertilization\/intracytoplasmic sperm injection: a systematic review","volume":"17","author":"Muharam R","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_6_15_1","article-title":"INSPECT\u2010SR: a tool for assessing trustworthiness of randomised controlled trials","author":"Wilkinson J","year":"2025","journal-title":"medRxiv"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez034"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.08.636"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae286"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.07.628"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaf097.254"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00796"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2024.01.027"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.18502\/ijrm.v17i9.5103"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.18502\/ijrm.v18i1.6197"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.02.036"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07387-4"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43043-025-00261-6"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.09.088"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.31083\/CEOG27951"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-025-01404-0"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.906602"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S226414"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14647273.2024.2316005"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2022.08.001"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-1592"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.702558"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05939-y"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/uog.70189"}],"container-title":["Ultrasound in Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/uog.70267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/uog.70267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/uog.70267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T21:49:02Z","timestamp":1787089742000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/uog.70267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/uog.70267"],"URL":"https:\/\/doi.org\/10.1002\/uog.70267","archive":["Portico"],"relation":{},"ISSN":["0960-7692","1469-0705"],"issn-type":[{"value":"0960-7692","type":"print"},{"value":"1469-0705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"2025-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}